Neogen Chemicals Q1FY26 profit jumps 36% to ₹19.44cr

What Neogen Chemicals reported this quarter

Neogen Chemicals Limited reported a stronger first quarter performance for the period ended June 30, 2026, with profit and revenue rising year-on-year. The company posted a standalone net profit of ₹19.44 crore, up 36.6% from ₹14.23 crore in the same quarter last year. Revenue from operations climbed to ₹252.28 crore from ₹184.58 crore, reflecting a higher scale of operations during the quarter. Alongside the earnings update, the company also disclosed board actions related to capital raising. The developments came amid a credit rating downgrade that has implications for the cost of borrowing.

Key standalone financial numbers: Q1FY26 vs Q1FY25

The headline numbers showed broad-based improvement year-on-year on the standalone basis. Revenue from operations rose 36.7% to ₹252.28 crore in Q1FY26 compared with ₹184.58 crore in Q1FY25. Net profit after tax increased 36.6% to ₹19.44 crore from ₹14.23 crore. Earnings per share (EPS) rose to ₹7.15 from ₹5.40, translating into a 32.4% increase. These figures indicate that profitability improved broadly in line with revenue growth, while per-share earnings also benefited.

What drove the revenue increase

The company attributed the rise in revenue to higher material consumption and inventory adjustments. These factors were cited as key drivers behind the improvement in revenue from operations over the year-ago quarter. The disclosure highlights that operational movement in inputs and inventories played a role in how the quarter shaped up. Beyond that, the update did not provide additional line-item detail on volumes, pricing, or segment-wise contributions.

EPS movement and what it signals

Neogen Chemicals reported EPS of ₹7.15 for Q1FY26 versus ₹5.40 in Q1FY25. The 32.4% rise in EPS suggests that the profit increase flowed through to shareholders on a per-share basis. While PAT grew faster than EPS in percentage terms, both moved in the same direction and remained tightly aligned. The company’s update did not specify whether the EPS change was influenced by any change in the share count.

Board meeting, approvals, and audit review

The financial results were approved by the Board of Directors at its meeting held on July 24, 2026. The results were reviewed by statutory auditors Chandabhoy & Jassoobhoy. These governance and compliance details are important for investors tracking the formal approval process and audit oversight around quarterly reporting.

Fund raise plan: up to ₹600 crore

Neogen Chemicals’ board granted in-principle approval to raise up to ₹600 crore through equity or debt instruments. The company framed this as part of its capital planning and strategic deployment needs. The disclosure did not specify the exact route, pricing, timeline, or mix between equity and debt. It also did not provide details on intended use of proceeds, beyond signalling capital deployment plans.

Crisil downgrade and the NCD coupon reset to 11.00%

The update noted that Crisil downgraded Neogen Chemicals’ ratings to A2. Following this downgrade, the coupon on the company’s non-convertible debentures (NCDs) was increased to 11.00%. This sequence matters because it links credit profile changes with a direct impact on borrowing costs. A higher coupon rate can raise interest outgo on the affected instruments, depending on outstanding amounts and terms.

Consolidated snapshot also referenced in the update

In addition to the standalone numbers, the provided context also referenced consolidated performance for the quarter ended June 30, 2026. It stated that consolidated profit after tax rose 67% year-on-year to ₹17 crore, while revenue increased 34% to ₹250 crore. The improvement was attributed to record revenues in the Organolithium portfolio and strong performance from the battery materials subsidiary, Neogen Ionics Limited. The disclosure did not provide a consolidated comparison base amount for the prior year quarter, beyond the percentage changes.

What investors will track from here

The combination of a planned ₹600 crore fund raise and a rating-linked coupon increase puts financing strategy in focus. Investors typically watch how companies balance growth capital needs with the cost of debt, especially after rating actions. The company’s next disclosures around the structure and timing of fundraising will likely be closely monitored. On the operating side, the quarter highlighted revenue growth supported by material consumption and inventory adjustments, and investors may look for consistency in subsequent quarters.

Key data table

Conclusion

Neogen Chemicals reported a sharp year-on-year rise in Q1FY26 standalone profit to ₹19.44 crore and higher revenue of ₹252.28 crore, with EPS improving to ₹7.15. The board’s in-principle approval to raise up to ₹600 crore adds a major capital-market item to watch. At the same time, the Crisil downgrade to A2 and the related NCD coupon hike to 11.00% underline the importance of funding costs in the near term. The next set of company disclosures on fundraising structure and financing terms will be key for tracking how these developments translate into execution.